Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment

Area of Science:

• Oncology
• Biochemistry
• Cancer Therapeutics

Background:

• Cancer is a leading global cause of death, with current treatments like chemotherapy and radiation having significant side effects due to low specificity.
• There is a critical need for novel cancer therapies that selectively target cancer cells without harming healthy tissues.
• Nutrient deprivation, specifically targeting amino acid auxotrophy in cancer cells, presents a promising therapeutic strategy.

Purpose of the Study:

• To explore the potential of L-Arginine (Arg) deprivation as an anticancer strategy.
• To investigate the efficacy of Arg-depriving enzymes (ADE) such as arginase, arginine decarboxylase (ADC), and arginine deiminase (ADI) in cancer therapy.
• To understand the mechanisms by which ADEs induce cancer cell death.

Main Methods:

• Utilizing ADEs to deplete L-Arginine, a vital amino acid crucial for cancer cell proliferation.
• Focusing on cancer types auxotrophic for L-Arginine due to low expression of key enzymes like argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), and ornithine transcarbamylase (OCT).
• Evaluating the impact of ADE treatment on cancer cell death pathways, including autophagy, apoptosis, and oxidative stress.

Main Results:

• L-Arginine auxotrophic cancer cells (e.g., hepatocellular carcinoma, colon cancer, leukemia, breast cancer) are sensitive to ADE treatment.
• ADEs induce cancer cell death through mechanisms including autophagy, apoptosis, and oxidative stress.
• Cancer cell progression and proliferation are arrested at specific cell cycle checkpoints by ADE therapy.

Conclusions:

• L-Arginine deprivation using ADEs is a promising strategy for targeting specific cancer types.
• ADEs offer a targeted approach to cancer therapy with potential for reduced side effects.
• These enzymes are currently in clinical trials and show potential as future anticancer agents.